Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03052127 · ClinicalTrials.gov registry record · Phase 1
Study in Subjects With Small Primary Choroidal Melanoma
A Phase 1 study, sponsored by Aura Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT03052127: Completed Phase 1 study, sponsored by Aura Biosciences.
NCT03052127 is a Phase 1 study that has completed, run by Aura Biosciences. The registered enrollment target is 57 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03052127, a Phase 1 study, has completed, sponsored by Aura Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.
Primary Outcome
Adverse events will be summarized by presenting the number and percentage of participants having any adverse event.
Interventions
- DRUG Light-activated AU-011
- DEVICE Laser Activation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2017-02-27 |
| Est. Completion | 2021-01-26 |
| Phase | Phase 1 |
What the finished NCT03052127 record still lists
NCT03052127 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Light-activated AU-011 is the first listed.
NCT03052127 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03052127 about?
NCT03052127 is a clinical study titled "Study in Subjects With Small Primary Choroidal Melanoma". The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.
What is the current status of trial NCT03052127?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2017-02-27. Estimated completion is 2021-01-26.
What interventions are being tested in trial NCT03052127?
The interventions under investigation include: Light-activated AU-011 (DRUG), Laser Activation (DEVICE).
Who is sponsoring clinical trial NCT03052127?
This trial is sponsored by Aura Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03052127's enrollment target sits among peer trials
57 901st of 2000 higher than 1,099 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI